Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant.

Slides:

Advertisements

Similar presentations

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.

Advertisements

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Improved Survival of Patients With End-Stage Heart.

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy,

Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management E.A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr,

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients James K. Kirklin, MD, David C. Naftel,

Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? Mary Bond, Stuart Mealing,

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Risk of coronary heart disease and risk of stroke in women with polycystic ovary syndrome: A systematic review and meta-analysis Sarah A. Anderson, John.

Bart S. Ferket, MD, PhD, Jonathan M

Comparison of chronic type A aortic dissection with acute type A dissection of short-term and long-term survival rate Qinghua Yuan, Hui Yu, Ujit Karmacharya,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant Jaimin R. Trivedi, MD,

Vigorous exercise in patients with hypertrophic cardiomyopathy

Shinichi Fukuhara, MD, Koji Takeda, MD, PhD, Paul A

Supplemental oxygen and surgical site infection: getting to the truth

Tissue and corneal donation and transplantation in the UK

Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol–remifentanil total i.v. anaesthesia with desflurane anaesthesia

Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without.

Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices Ranjit John, MD, Kenneth Liao,

Duration of inotropic support after left ventricular assist device implantation: Risk factors and impact on outcome Soren Schenk, MD, Patrick M. McCarthy,

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication? Nishant D. Patel, BA, Jason.

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C

Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes

Organ transplantation: historical perspective and current practice

Exercise hemodynamics in hypertrophic cardiomyopathy identify risk of incident heart failure but not ventricular arrhythmias or sudden cardiac death

Outcomes after implantation of partial-support left ventricular assist devices in inotropic- dependent patients: Do we still need full-support assist devices?

Patient-reported causes of heart failure in a large European sample

Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations Offer Amir, Tuvia Ben-Gal,

Atrial fibrillation: Improvement in identification and stroke preventive therapy —Data from the UK Clinical Practice Research Datalink, 2000–2012 A.C.E.

Nicholas G. Smedira, MD, Katherine J. Hoercher, RN, Dustin Y

Should Patients 60 Years and Older Undergo Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices? Jeremiah G. Allen, MD, Arman.

Neal A. Chatterjee et al. JCHF 2014;2:

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9- Year Experience Jeffrey A. Morgan, MD, Pauline H. Go, MD, Linnea.

Fabio De Giorgio, Vincenzo M. Grassi, Matteo Polacco, Vincenzo L

Jerry D. Estep et al. JCHF 2013;1:

International Journal of Cardiology

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

International Journal of Cardiology

Long-term follow-up of mitral valve regurgitation��Importance of mitral valve pathology and left ventricular function on survival Krister Lindmark,

Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression Corline Brouwers, Stefan.

Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department J.M. Poldervaart,

Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? Mary Bond, Stuart Mealing,

Long-term survival after vascular surgery: Specific influence of cardiac factors and implications for preoperative evaluation Martin R. Back, MD, Fabian.

Ruth H. Keogh, Sanja Stanojevic Journal of Cystic Fibrosis

Posttransplant Outcomes Among Septuagenarians Bridged to Transplantation With Continuous-Flow Left Ventricular Assist Devices Shinichi Fukuhara, MD,

Mechanical Circulatory Support Pathways That Maximize Post-Heart Transplant Survival Tara Karamlou, MD, MS, Jill Gelow, MD, Brian S. Diggs, PhD, Frederick.

Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study Victor Shi, Michele Senni, Hendrik.

International Journal of Cardiology

Is age a predictor of mortality in a UK medical high dependency unit?

Francisco A. Arabía, MD, MBA, Carmelo A

Normal values for myocardial deformation within the right heart measured by feature- tracking cardiovascular magnetic resonance imaging Boyang Liu, Ahmed.

Early Outcomes With Marginal Donor Hearts Compared With Left Ventricular Assist Device Support in Patients With Advanced Heart Failure Erin M. Schumer,

Left ventricular assist device implantation after acute anterior wall myocardial infarction and cardiogenic shock: A two-center study Nicholas C. Dang,

Editorial II: Solid as a ROC

Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant.

Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled.

Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices Forum Kamdar, MD, Ranjit John,

Improved Survival and Decreasing Incidence of Adverse Events With the HeartMate II Left Ventricular Assist Device as Bridge-to-Transplant Therapy Ranjit.

Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation Finlay A. McAlister,

Optimal timing for heart transplantation in patients bridged with left ventricular assist devices: Is timing of the essence? Chase R. Brown, MD, Fabliha.

Left Ventricular Assist Device Performance With Long-Term Circulatory Support: Lessons From the REMATCH Trial Walter P. Dembitsky, MD, Alfred J. Tector,

Daisuke Yoshioka, MD, Hiroo Takayama, MD, Arthur R. Garan, MD, Veli K

Infectious Complications in Patients With Left Ventricular Assist Device: Etiology and Outcomes in the Continuous-Flow Era Veli K. Topkara, MD, Sreekanth.

International Journal of Cardiology

Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation Marat Fudim, MD, Mary E. Davis, MS,

Presentation transcript:

Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant (BTT) program Aileen Clarke, Ruth Pulikottil-Jacob, Martin Connock, Gaurav Suri, Ngianga-Bakwin Kandala, Hendramoorthy Maheswaran, Nicholas R. Banner, Paul Sutcliffe International Journal of Cardiology Volume 171, Issue 3, Pages 338-345 (February 2014) DOI: 10.1016/j.ijcard.2013.12.015 Copyright © 2013 The Authors Terms and Conditions

Fig. 1 Time to event analyses using the UK NHS BTDB, showing: i) Observed survival (95% CI) to 10% at risk and modeled survival (solid line) while supported with an LVAD (patients were censored if alive at end of follow up, on removal of a LVAD for myocardial recovery and on receipt of a transplant); ii) observed survival (95% CI) to 10% at risk and modeled survival (solid line) while supported with medical management (patients were censored if alive at end of follow up, if removed from the transplant list, and on receipt of a transplant); iii) time to heart transplant (patients were censored on death, on removal from the transplant list and if at end of follow up they had not received a donor heart); iv) survival after heart transplant (patients were censored if alive at end of follow up after heart transplant. (Please note different scales for x axes). International Journal of Cardiology 2014 171, 338-345DOI: (10.1016/j.ijcard.2013.12.015) Copyright © 2013 The Authors Terms and Conditions

Fig. 2 A: Cost effectiveness plane; and B: cost-effectiveness acceptability curves (CEAC) for 3, 10 and lifetime horizons for the comparison of LVADs versus medical management with inotropes. International Journal of Cardiology 2014 171, 338-345DOI: (10.1016/j.ijcard.2013.12.015) Copyright © 2013 The Authors Terms and Conditions

Fig. 3 Tornado plot of univariate sensitivity analyses around base case input values. Note: changes to monthly cost of the LVADs and medical management (MM) groups included a 30% increase or decrease to both pre-HT and post-HT costs. International Journal of Cardiology 2014 171, 338-345DOI: (10.1016/j.ijcard.2013.12.015) Copyright © 2013 The Authors Terms and Conditions